Home › Upcoming votes › HCW Biologics Inc.
The deadline as the proxy statement states it: “Votes submitted by telephone or through the internet must be received by 11:59 p.m. Eastern Time, on November 16, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in HCW Biologics Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | A broker non-vote occurs when the beneficial owner of shares fails to provide the broker, bank or other nominee that holds the shares with | Board | For | — |
From HCW Biologics Inc.’s Form 8-K, filed June 23, 2025, for the meeting held June 17, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Scott T. Garrett | 98% | — |
| Elect Director: Gary M Winer | 25% | — |
| 2. The appointment of Crowe LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, | 99.9% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.